Ma Brigette B Y, Poon Terence C W, To K F, Zee Benny, Mo Frankie K F, Chan Charles M L, Ho Stephen, Teo Peter M L, Johnson Phillip J, Chan Anthony T C
Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territory, Hong Kong SAR, China.
Head Neck. 2003 Oct;25(10):864-72. doi: 10.1002/hed.10307.
This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (NPC).
Seventy-eight Chinese were recruited from October 1995 to July 1997 at the Prince of Wales Hospital, Hong Kong. Pretreatment immunohistochemical preparations of the primary tumor were made, and clinical data were collected prospectively until October 30, 2000. The markers were correlated with overall survival (OS), disease-free survival (DFS), time to progression (TTP), and UICC stage.
On univariate analysis, EGFR expression correlated with poorer OS (p =.0001), DFS (p =.01), shorter TTP (p =.0001), and advanced T stage (p =.036). Strong EGFR expression, when compared with weak or moderate, was associated with poorer OS (p =.04) and shorter TTP in a subgroup of patients with UICC stage III-IV disease. HER2 expression was associated with advanced UICC stage (p =.006). The presence of p53 expression correlated with poorer DFS (p =.01) and a trend toward shorter TTP (p =.06). No correlation was found with Ki67-antigen or MVD. On multivariate analysis, only EGFR expression was significantly linked to shorter OS and TTP.
EGFR expression in undifferentiated NPC is associated with a poor clinical outcome. A prognostic role of p53 and HER2 expression is suggestive but not consistently defined in this study. The relatively high prevalence of positive staining for EGFR supports the use of molecular targeted therapy in this disease.
本研究前瞻性地探讨了p53癌蛋白(p53)、Ki67抗原(Ki67)、肿瘤血管生成(MVD)、表皮生长因子受体(EGFR)和HER2受体蛋白(HER2)表达在中国未分化鼻咽癌(NPC)患者中的预后作用。
1995年10月至1997年7月,在香港威尔士亲王医院招募了78名中国患者。制备了原发性肿瘤的预处理免疫组织化学标本,并前瞻性地收集临床数据直至2000年10月30日。将这些标志物与总生存期(OS)、无病生存期(DFS)、进展时间(TTP)和国际抗癌联盟(UICC)分期进行关联分析。
单因素分析显示,EGFR表达与较差的OS(p = 0.0001)、DFS(p = 0.01)、较短的TTP(p = 0.0001)以及晚期T分期(p = 0.036)相关。与弱或中度EGFR表达相比,强EGFR表达与UICC III-IV期疾病患者亚组中较差的OS(p = 0.04)和较短的TTP相关。HER2表达与晚期UICC分期相关(p = 0.006)。p53表达的存在与较差的DFS(p = 0.01)以及TTP缩短的趋势相关(p = 0.06)。未发现与Ki67抗原或MVD相关。多因素分析显示,只有EGFR表达与较短的OS和TTP显著相关。
未分化NPC中EGFR表达与不良临床结局相关。p53和HER2表达的预后作用具有提示性,但在本研究中未得到一致定义。EGFR阳性染色的相对高发生率支持在该疾病中使用分子靶向治疗。